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Nowadays it is well accepted that in Parkinson’s disease (PD), the neurodegenerative
process occurs in stages and that damage to other areas precedes the neuronal loss in
the substantia nigra pars compacta, which is considered a pathophysiological hallmark of
PD. This heterogeneous and progressive neurodegeneration may explain the diverse
symptomatology of the disease, including motor and non-motor alterations. In PD, one of
the first areas undergoing degeneration is the locus coeruleus (LC). This noradrenergic
nucleus provides extensive innervation throughout the brain and plays a fundamental
neuromodulator role, participating in stress responses, emotional memory, and control of
motor, sensory, and autonomic functions. Early in the disease, LC neurons suffer
modifications that can condition the effectiveness of pharmacological treatments, and
importantly, can lead to the appearance of common non-motor symptomatology. The
noradrenergic system also exerts anti-inflammatory and neuroprotective effect on
the dopaminergic degeneration and noradrenergic damage can consequently condition
the progress of the disease. From the pharmacological point of view, it is also important to
understand how the noradrenergic system performs in PD, since noradrenergic
medication is often used in these patients, and drug interactions can take place when
combining them with the gold standard drug therapy in PD, L-3,4-dihydroxyphenylalanine
(L-DOPA). This review provides an overview about the functional status of the
noradrenergic system in PD and its contribution to the efficacy of pharmacological-
based treatments. Based on preclinical and clinical publications, a special attention will be
dedicated to the most prevalent non-motor symptoms of the disease.
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INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the presence
of a-synuclein protein aggregates in the form of Lewy bodies in specific brain regions. These
aggregates may be responsible for the onset and progression of the disease likely by promoting
mitochondrial dysfunction, microglial activation, and neuroinflammatory responses, but they do
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not appear all over the brain at the same time. Indeed, recent
publications have suggested that the a-synuclein pathology
begins in the gut and travels via the vagal nerve up to the
brain where it spreads following the six stages defined by Braak
and colleagues (Ulusoy et al., 2013; Kim et al., 2019). Although
historically the hallmark of the disease has been focused on the
degeneration of the substantia nigra pars compacta (SNc), it is
now well accepted that the spread of a-synuclein in the brain
occurs in stages and that damage to other areas precedes the
degeneration of SNc neurons, affecting glutamatergic,
noradrenergic, serotonergic, histaminergic, and cholinergic
projection cells (Del Tredici et al., 2002; Braak et al., 2003).
This heterogeneous, progressive neurodegeneration may explain
the diverse symptomatology of PD, which includes motor and
non-motor alterations (Chaudhuri and Schapira, 2009). Indeed,
PD is more likely to be a multisystem disorder rather than a pure
motor disease.
According to Braak’s theory (Braak et al., 2004), the first a-
synuclein aggregates in the central nervous system appear in the
anterior olfactory structures and the dorsal motor nucleus of the
vagus nerve, following by lower raphe system and the locus
coeruleus (LC) in stage 2. It is not until stage 3 that the SNc is
affected together with the amygdala, tegmental pedunculopontine
nucleus, and the higher raphe nuclei, among others. During stage 4,
a-synuclein spreads to the hippocampal formation and specific
cortical areas and finally, in the last two stages (5 and 6), almost the
whole cortex is damaged. This pattern of a-synuclein propagation
between interconnected nuclei has also been mimicked in animal
models in which a-synuclein was overexpressed by means of viral
vector administration in peripheral structures (Rey et al., 2013;
Ulusoy et al., 2013; Ulusoy et al., 2017; Rusconi et al., 2018). The
pathological process underlying PD would consist of a prodromal
period followed by a symptomatic one when the disease is often
diagnosed. The presymptomatic or prodromal phase (stages 1–3) is
often characterized by olfactory dysfunction, autonomic
dysregulation, pain, sleep, and mood disorders while the
symptomatic phase (stages 4–6) is accompanied by the classical
somatomotor symptoms and impaired cognitive functioning
(Chaudhuri and Schapira, 2009; Braak and Del Tredici, 2016).
Among the brain areas that undergo degeneration in the
prodromal phase, the LC deserves special attention for being one
of the first nuclei to develop Lewy bodies, and because LC
dysfunction may be related to several of the non-motor
symptoms observed in the disease. Here, we will review the
functional status of the LC in PD using data from experimental
models and patients. We will also analyze the potential role of the
LC in PD-associated neuroinflammation, the appearance of non-
motor complications, and the pharmacological therapies.
THE LOCUS COERULEUS
The LC is a bilateral nucleus located in the upper dorsolateral
pontine tegmentum and is considered the principal
noradrenergic nucleus in the central nervous system (Amaral
and Sinnamon, 1977). Although noradrenergic neurons are the
biggest cell population, GABAergic interneurons also inhabit the
LC making synapses and efficiently inhibit the noradrenergic
neurons (Aston-Jones et al., 2004; Jin et al., 2016; Breton-
Provencher and Sur, 2019). Neurochemical content and
receptor expression are also very heterogeneous containing
adrenergic, GABAergic, serotonergic, glutamatergic, µ-opioid,
orexin/hypocreatin, nicotinic acetylcholine, and cannabinoid
receptors (reviewed in Berridge and Waterhouse, 2003;
Schwarz and Luo, 2015). LC noradrenergic cells, as happens
with SNc neurons, also contains neuromelanin which makes
them specially vulnerable to neurodegeneration in PD (reviewed
in Martin-Bastida et al., 2017 and Vila, 2019).
Despite being a tiny nucleus, the LC shows an enormous
projecting network, influencing the activity of nuclei all over the
brain. It sends descending projections to the spinal cord
(Westlund et al., 1983) and densely innervates ascending areas
of the CNS as the amygdala, superior colliculus, paraventricular
thalamic nucleus, hippocampus, olfactory bulb, dorsal raphe, and
cortex, including prefrontal, orbitofrontal, anterior cingulate,
and primary motor cortices (Fallon et al., 1978; Shipley et al.,
1985; Loughlin et al., 1986; Kim et al., 2004; Chandler et al., 2014;
Schwarz et al., 2015; Kempadoo et al., 2016; Takeuchi et al., 2016;
McCall et al., 2017; Beas et al., 2018; Li L. et al., 2018). The SNc
and the ventral tegmental area also receive modest noradrenergic
innervation from the LC (Baldo et al., 2003; Mejías-Aponte et al.,
2009). By contrast, those areas with intense dopaminergic
innervation as the nucleus accumbens or the striatum show
discrete noradrenergic innervation (Mason and Fibiger, 1979;
Berridge et al., 1997; Delfs et al., 1998; Fitoussi et al., 2013). As for
the afferences, the LC also receives a large variety of inputs
including those from the paragigantocellularis, prepositus
hypoglossi, dorsal raphe, superior colliculus, prefrontal cortex,
or the SNc (Aston-Jones et al., 1986; Devoto et al., 2005b;
Delaville et al., 2011; Lu et al., 2012; Breton-Provencher and
Sur, 2019).
It is interesting to mention that although the LC does not
project to nuclei highly innervated by the dopaminergic system,
it can still influence dopaminergic transmission distally. Devoto
and collaborators have extensively characterized that LC-
tyrosine hydroxylase positive fibers can co-release not only
noradrenaline (NA) but also dopamine (DA) in the cortex,
including prefrontal, parietal, and occipital cortices involving
a2-adrenoceptor-mediated mechanisms (Devoto et al., 2001;
Devoto et al., 2003; Devoto et al., 2004; Devoto et al., 2005a;
Devoto et al., 2005b). More recently, other authors have also
supported that LC activation promotes DA release in the
thalamus and hippocampus, contributing to stress and
cognitive functions (Smith and Greene, 2012; Kempadoo et al.,
2016; Yamasaki and Takeuchi, 2017; Beas et al., 2018).
In view of the dense noradrenergic projection network, it is easy
to understand the implication of this nucleus in many physiological
functions and pathological conditions. Experimental preclinical
models have demonstrated the implication of the LC in arousal,
cognition, anxiety, depression, pain, attention, and locomotor
control (Aston-Jones and Bloom, 1981; Carter et al., 2010; Curtis
et al., 2012; Sara and Bouret, 2012; Chandler et al., 2014; McCall
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et al., 2015; Szot et al., 2016; Benarroch, 2017; Hirschberg et al.,
2017; McCall et al., 2017; Beas et al., 2018; Breton-Provencher and
Sur, 2019; Llorca-Torralba et al., 2019). The availability of new
technologies, as opto- and chemogenetics, that allow efficient
activation/inhibition of specific anatomical projections or cellular
subtypes, has provided a better understanding of those functions
and unraveled that the LC is a more heterogeneous nucleus than
previously proposed. Interestingly many of the pathological
situations triggered by the dysfunction of the LC are present in
PD, stressing the role of this nucleus in the development and




In the last decades, researchers have shown increasing interest in
further understanding the pathophysiological basis of the non-
motor symptoms present in PD with special focus on the
noradrenergic system. In the preclinical studies, viral-vector-
induced, gene-mutated, or neurotoxin-based animal models are
regularly used although the vast majority of the data come from
these latter ones.
Anatomical studies using the unilaterally 6-hydroxydopamine
(6-OHDA)-lesioned rat model show that the number of LC neurons
is not affected by the DA loss (Miguelez et al., 2011b; Ostock et al.,
2018) but NA levels in different projection areas are variably
decreased. In the prefrontal cortex of the lesioned hemisphere,
some authors found unchanged (Delaville et al., 2012a; Delaville
et al., 2012b) or reduced NA concentrations (Shin et al., 2014;
Ostock et al., 2018). Similarly, other areas with sparse noradrenergic
innervation, as the striatum, show unchanged or lower NA levels
(Shin et al., 2014; Ostock et al., 2018). Bilateral models of 6-OHDA
show, however, more robust NA deficits in the cortex and striatum
(Vieira et al., 2019). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP)-treated monkeys exhibit clear noradrenergic damage,
including LC cell loss, lower NA concentrations in several brain
regions, and reduced noradrenergic innervation of the SNc and the
subthalamic nucleus (Pifl et al., 1991; Masilamoni et al., 2017). Some
publications have also reported low NA striatal and cortical tissue
content in MPTP mice (Luchtman et al., 2009; Nayyar et al., 2009;
Ando et al., 2018). Indeed, MPTP reproduces better than 6-OHDA
the heterogeneous neuronal damage produced in PD, as recently
shown by a publication using matrix-assisted laser desorption-
ionization mass spectrometry (Kadar et al., 2014). Evidence
regarding the integrity of the noradrenergic system in transgenic
mice models of PD is more scarce but also stresses noradrenergic
impairment. Thus, reduced tyrosine hydroxylase positive cells and
a-synuclein aggregations in the LC have been demonstrated in
PINK1 knockout rats (Grant et al., 2015; Cullen et al., 2018), LRRK,
and parkin knockout mice (Von Coelln et al., 2004; Giaime et al.,
2017). However, in transgenic mice overexpressing human A53T a-
synuclein, although having lower NA levels at the level of the
striatum, olfactory bulb, and spinal cord, TH positive cells in the LC
expressed modest a-synuclein aggregates but remained intact in
number (Giasson et al., 2002; Sotiriou et al., 2010). These
noradrenergic dysfunctions are accompanied by behavioral
deficits, such as early vocalization and swallowing deficits.
It is also interesting to stress that in parkinsonian conditions,
the noradrenergic system may contribute in some extent to the
loss of dopaminergic function. In animals lesioned with 6-
OHDA, noradrenergic transporter (NET) are increased
possibly for compensating for the severe DA loss (Chotibut
et al., 2012). Indeed, NET can reuptake not only NA but also
DA in those regions with sparse DA innervation (Morón et al.,
2002). In this line, some publications support that in absence of
DA transporters, NET reuptakes L-DOPA-derived DA in the
striatum and other areas, playing a possible role in L-DOPA
induced dyskinesia (LID), as later discussed.
Apart from the anatomical and neurochemical changes, few
electrophysiological studies using anaesthetized 6-OHDA
lesioned animals, have revealed that experimental DA
degeneration also impacts LC neuron basal activity and its
response to antidepressant agents in parkinsonian rodents.
Regarding the electrophysiological changes, increased and
decreased activity was reported by different authors (Wang
et al., 2009; Miguelez et al., 2011a; Miguelez et al., 2011b). This
discrepancy may rely in methodological differences that could
imply direct noradrenergic damage produced by the neurotoxins
(Szot et al., 2016). On the other hand, in control rats,
serotonergic and noradrenergic antidepressants interact with
L-DOPA when administered together (see below). Using the
forced swimming test, control rats subchronically treated with L-
DOPA and fluoxetine showed reduced efficacy of the
antidepressant drug, while coadministration of the NET
blocker reboxetine and L-DOPA provided the opposite effect
(Miguelez et al., 2013). At the behavioral level, regardless
inconsistencies found through the scientific publications,
park inson ian an ima l s t end to mimic the human
symptomatology showing motor but also non-motor
impairments (Titova et al., 2017). An array of studies report
that rodents lesioned with 6-OHDA or MPTP show anxious and
depressive behavior, pain, cognitive, and sleep disturbances
(Monaca et al., 2004; Pérez et al., 2009; Berghauzen-
Maciejewska et al., 2014; Vo et al., 2014; Kamińska et al., 2017;
Charles et al., 2018; Campos et al., 2019; Domenici et al., 2019),
more notably in bilateral models of the disease (Ferro et al., 2005;
Tadaiesky et al., 2008; Santiago et al., 2010; Bonito-Oliva et al.,
2014; Vieira et al., 2019). Although the participation of other
nuclei cannot be ruled out, the role of the LC in the mentioned
functions is widely accepted.
Although preclinical data to large extent support the
noradrenergic affection in parkinsonian models, several
discrepancies exist, which may be due to methodological
variations. In this regard, especially when using the neurotoxin
6-OHDA, it should be considered that lesion protocols vary
considerably among the studies, including key steps like animal
age, toxin dose and injection site, magnitude of the lesions, and
administration of the non-selective NET blocker desipramine to
protect noradrenergic neurons from the 6-OHDA toxicity.
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Genetic and a-synuclein based models are less often used with
considerable results variation among the studies. The use of
other neurotoxins as MPTP seems to provide results that are
more consistent.
Clinical Evidence
In line with the aforementioned findings reported in animal
models of PD, there is substantial evidence showing
degeneration of the noradrenergic system in PD patients.
Numerous anatomical post mortem studies in PD brains have
documented a moderate to severe cell loss (around 30–90%) and
Lewy body pathology in the LC, equal in magnitude throughout
the rostral-caudal parts of the nucleus (Gaspar and Gray, 1984;
Chan-Palay and Asan, 1989; German et al., 1992; Bertrand et al.,
1997; Zarow et al., 2003; McMillan et al., 2011). Specifically,
neuromelanin-containing medium-size LC neurons present
somatic and dendritic alterations, whereas smaller non-
noradrenergic LC cells do not show severe pathological
changes (Patt and Gerhard, 1993).
Although in vivo positron emission tomography imaging
studies using non-specific ligands failed to identify the
noradrenergic damage, more recent neuromelanin-sensitive
magnetic resonance studies have found progressive loss of the
LC signal in both idiopathic and genetic PD patients and even a
lower signal in those PD patients with depressive symptoms
(Sasaki et al., 2006; Castellanos et al., 2015; Schwarz et al., 2017;
Wang et al., 2018). 18F-dopa positron emission tomography
imaging, as an index of monoaminergic nerve terminal
function, have also demonstrated a reduced uptake in the LC,
indicating progressive loss of noradrenergic terminal function
(Pavese et al., 2011).
While the relationship between a-synuclein accumulation and
neuronal death is not fully understood, it has been proposed that
this protein burden may lead to neuronal dysfunction/degeneration
and, therefore, impair neurotransmission (Espay et al., 2014). As
explained before, Braak and colleagues established six levels of
degeneration over the course of the disease where the
noradrenergic impairment would occur earlier than the
dopaminergic one and the subsequent primary motor symptoms.
It has further been proposed that a-synuclein pathology in the LC
not only precedes, but may also be of greater magnitude than that
occurring in the SNc, a finding that persists across disease stages
(Zarow et al., 2003). These results suggest that LC dysfunction may
directly contribute to disease onset and progression rather than be a
collateral consequence.
Consistent with LC neuron loss and degeneration, there is a
decreased noradrenergic innervation of LC target structures,
including the prefrontal and motor cortex, striatum, thalamus,
hypothalamus, and cerebellum (Kish et al., 1984; Shannak et al.,
1994; Pavese et al., 2011; Pifl et al., 2012; Sommerauer et al.,
2018b). The atrophy of tyrosine hydroxylase-containing axons is
not restricted to the central nervous system, and a prominent loss
of noradrenergic innervations of the peripheral autonomic
system has been demonstrated, including in the left cardiac
ventricle (Hakusui et al., 1994; Takatsu et al., 2000; Slaets
et al., 2015).
Although plasma NA levels are elevated in de novo PD
patients (Ahlskog et al., 1996), neurochemical studies have
reported lower levels of the neuronal NA metabolite
dihydroxyphenylglycol in the cerebrospinal fluid (Goldstein
et al., 2012), as well as marked reduction of DA-beta-
hydroxylase activity, an enzyme responsible for hydroxylation
of DA to NA, in parkinsonian patients (Hurst et al., 1985;
O’Connor et al., 1994). Regarding changes in adrenergic
receptors in PD, an in vitro autoradiographic study showed
upregulation of a1- and b1- and reduced density of a2-
adrenoceptors in the prefrontal cortex of post mortem
parkinsonian patients (Cash et al., 1984).
Despite some discrepancies in animal models, both
preclinical and clinical studies support the notion that the
noradrenergic system is impaired in parkinsonism. This is
important for understanding the complexity of the
neurodegenerative process and should be taken into account
when administering drugs whose pharmacological effect relies on
the integrity of this system.
CLINICAL IMPLICATIONS OF
NORADRENERGIC DYSFUNCTION IN PD
The degeneration of the noradrenergic system in the CNS and
periphery occurring in PD is associated with a broad spectrum of
non-motor symptoms that encompass autonomic, behavioral, and
cognitive parameters. The appearance of these symptoms and signs
cannot be just attributed to an alteration in the functioning of the
noradrenergic system, as they are also known to be associated with
deficits in other neurotransmission systems such as cholinergic,
serotonergic, GABAergic, or glutamatergic (Schapira et al., 2017).
However, in this review, we will focus on non-motor complications
appearing in the prodromal phase of the disease that, apart from
other neurotransmitters’ abnormalities, implicate malfunctioning of
LC neurons.
In accordance with predicted Braak’s stages, the different
clinical features due to noradrenergic dysfunction can be
observed along the progression of the disease (Halliday et al.,
2011) and, often appear before motor symptoms onset. Detecting
noradrenergic impairment could be used as a diagnostic
biomarker for early detection of the neurodegeneration,
providing an opportunity for intervention with disease-
modifying therapies (Betts et al., 2019).
Autonomic Disturbances
Sympathetic autonomic dysfunction is a common clinical feature of
PD and may precede motor symptomatology, becoming more
prevalent as the disease progresses (Schapira et al., 2017). The
most common dysautonomic symptoms are orthostatic
hypotension, urogenital dysfunction, and constipation (Martinez-
Martin et al., 2015), but PD patients can also suffer fatigue,
thermoregulatory dysregulation, excessive perspiration, or postural
light-headedness. Autonomic dysfunction has a heterogeneous
manifestation and its progression is not predictable, however, it is
associated with reduced autonomy and a decline in quality of life,
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regardless of severity or duration of the disease (Leclair-Visonneau
et al., 2018). The orthostatic hypotension affects 30–58% of PD
patients (Goldstein, 2006) and has been linked to peripheral
sympathetic cardiovascular denervation and also in a certain
degree to central autonomic involvement. PD patients with
defined symptomatic orthostatic hypotension exhibit decreased
LC neuromelanin signal on magnetic resonance studies
(Sommerauer et al., 2018a) and low plasma levels of NA, which is
associated with both supersensitivity of vascular adrenergic
receptors and an up-regulation of platelet a2-adrenoceptors
(Senard et al., 1990). As a consequence of a reduced capacity to
adapt the peripheral vasculature and cerebral perfusion pressure PD
patients can often manifest postural light-headedness and syncope
(Sharabi et al., 2008). Constipation and prolonged gastrointestinal
transit time affect more than 80% of PD patients and, in some cases,
may lead to megacolon (for review see Cersosimo and Benarroch,
2008). Although defecation dysfunction seems to be multifactorial,
one of the proposed pathophysiological mechanisms is the
accumulation of a-synuclein immunoreactive Lewy bodies in
sympathetic ganglia (Wakabayashi and Takahashi, 1997). Urinary
and sexual dysfunctions are also late features of PD related to
degeneration of brain regions that innervate the bladder, among
them the LC (Micieli et al., 2003; Park and Stacy, 2009).
Sleep Disorders
Sleep disturbances are among the most frequent PD symptoms,
affecting some 60–98% of patients (Stacy, 2002). Common sleep
disorders include excessive daytime somnolence, nocturnal
wakefulness, sleep attacks, REM sleep behavior disorder, or
restless leg syndrome. All these sleep impairments can be early
premotor manifestations and related to LC dysfunction as
underlying mechanism, since this nucleus contributes to the
control of arousal and sleep-wake cycle (Carter et al., 2010). In
fact, post mortem examinations of patients with REM sleep behavior
disorder without motor symptoms revealed neuronal loss and Lewy
bodies in the LC (Uchiyama et al., 1995). A recent magnetic
resonance study further linked LC neuromelanin levels with
amount of REM sleep without atonia in PD patients
(Sommerauer et al., 2018a). Clinical management of sleep
disorders in PD is complex because most of the antiparkinsonian
drugs can alter sleep architecture and induce sleepiness as a side
effect. Nevertheless clonazepam or melatonin are often prescribed
(Gagnon et al., 2006).
Depression
Depression affects up to 40% of PD patients and may precede the
onset of motor symptomatology (Cummings, 1992; Shiba et al.,
2000; Cummings et al., 2019). There is strong evidence for a
correlation between noradrenergic function and depression in PD
patients. In fact, neuroimaging and neuropathological studies have
demonstrated reduced LC projections to limbic brain areas
(cingulate cortex, thalamus, ventral striatum, or amygdala), as well
as gliosis and cell loss at LC level, which was more pronounced in
patients with higher frequency of depression or anxiety (Remy et al.,
2005; Frisina et al., 2009). As in major depression, selective
serotonin reuptake inhibitors, tricyclic antidepressants, serotonin
and NA reuptake inhibitors, and monoamine oxidase inhibitors are
used in the pharmacotherapy, with partial effect, probably
influenced by the neurodegeneration of the serotonergic and
noradrenergic systems (Ryan et al., 2019). The use of
antidepressant that do not target monoaminergic systems may
potentially offer benefit in these patients (Vanle et al., 2018).
Cognitive Manifestations
The loss of LC neurons and decreased noradrenergic innervation
of forebrain targets are associated with cognitive dysfunction in
PD (Cash et al., 1987; Rommelfanger and Weinshenker, 2007;
Vazey and Aston-Jones, 2012; Sommerauer et al., 2018a). In early
PD, subtle cognitive deficits include difficulty in executing
functioning, particularly cognitive flexibility, which is the
capacity to update and redirect attention when the
environmental or homeostatic conditions change. Flexibility in
cognitive processing is an essential function of prefrontal cortex
and it has been proposed that loss of prefrontal noradrenergic
input may contribute to this prodromal cognitive deficit (Vazey
and Aston-Jones, 2012). In late stage PD, dementia can occur
with a prevalence of 24–31% (Aarsland et al., 2005). Although
dementia in PD is related to a substantial reduction in cortical
cholinergic markers, there is also evidence for a more severe loss
of noradrenergic input from the LC to cortical areas (Chan-Palay
and Asan, 1989). The severity of dementia has been linked to the
loss of LC neurons in some studies (Zweig et al., 1993; Del
Tredici and Braak, 2013; Li et al., 2019).
NORADRENALINE, NEUROINFLAMMATION,
AND NEUROPROTECTION
It is important to mention that NA might protect DA neurons
from damage and therefore, integrity of the noradrenergic
system may condition the progression of the disease. In this
sense, preclinical data from MPTP mice and marmosets suggest
that damaging the LC leads to a loss of DA neurons in the SNc
followed by more pronounced motor deficits (Mavridis et al.,
1991; Marien et al., 1993; Bing et al., 1994; Fornai et al., 1995;
Fornai et al., 1997; Yao et al., 2015; Li Y. et al., 2018). Conversely,
the damage produced by MPTP is reduced when the synthesis of
NA is boosted (Kilbourn et al., 1998; Archer, 2016) or the NET is
knocked out (Rommelfanger et al., 2004). A recent publication
using mutant mice characterized by the progressive degeneration
of dopaminergic neurons demonstrated that chronic
pharmacological NET blockade ameliorates such degeneration
and the subsequent motor impairment (Kreiner et al., 2019).
Peripheral administration of the NET blocker atomoxetine also
reduced DA damage in a lipopolysaccharide inflammatory rat
model of PD (Yssel et al., 2018). Direct noradrenergic damage by
the administration of the neurotoxin N-(2-chloroethyl)-N-ethyl-
2-bromobenzylamine (or DSP-4) also produces motor deficits
and DA cell loss in control rats (Af Bjerkén et al., 2019). In
another recent publication, DSP-4 developed motor and non-
motor symptoms in control mice and exacerbated motor
disability in mice rendered parkinsonian by the injection of
lipopolysaccharide (Song et al., 2019). Some studies performed
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in 6-OHDA lesioned rodents also suggest that noradrenergic
lesions in parkinsonian rats augment dopaminergic neuron
vulnerability (Ostock et al., 2014) leading to lower DA levels
(Srinivasan and Schmidt, 2003) and worsening motor
performance (Srinivasan and Schmidt, 2003; Srinivasan and
Schmidt, 2004; Wang et al., 2010; Shin et al., 2014; Ostock
et al., 2018). Other studies using the same 6-OHDA model
failed, however, to reproduce the latter findings (Delaville
et al., 2012a; Guimarães et al., 2013; Ostock et al., 2014; Shin
et al., 2014).
The mechanism underlying the neuroprotective effect of NA
on DA degeneration is not well understood, although several
lines of evidence point at the anti-inflammatory properties of NA
as one factor responsible of such an effect. Both PD patients and
animal models of the disease show reactive astrogliosis, astrocytic
dysfunction, and microglial activation, which has been proposed
as the origin of neuroinflammation (Ouchi et al., 2005; Gerhard
et al., 2006; Glass et al., 2010; Terada et al., 2016; Liu et al., 2017;
Tsutsumi et al., 2019). Importantly, by controlling microglial
activation NA is able to halt the damage of dopaminergic
neurons. Studies performed in cell cultures and animal models
suggest that NA suppresses neuroinflammation by acting, at least
in part, on b2-adrenergic receptors, which are highly expressed in
glial cells (Mori et al., 2002; Tanaka et al., 2002; Yao et al., 2015).
Low concentrations of NA or long acting b2-agonists are able to
inhibit the microglial production and release of chemokines,
interleucines, tumor necrosis factor (TNF-a), superoxide or
nitric oxide, among others, (Mori et al., 2002; McNamee et al.,
2010a; Qian et al., 2011) or to stimulate the synthesis of
interleukin-1 receptor antagonists (McNamee et al., 2010b).
Pharmaceutical strategies for increasing NA levels also
attenuate nigral microglial activation and ameliorate the
behavioral deficits in parkinsonian rats (Yssel et al., 2018).
Other authors have also proposed that in addition to the b2-
mediated mechanisms, NA can impact inflammation by
inhibiting NADPH oxidase-generated superoxide (Jiang et al.,
2015). Additionally, b2-agonists and NET inhibitors can also
induce release of neurotrophic factors from astrocytes promoting
neuroprotection and regeneration (Yssel et al., 2018).
By contrast, NA deficit accelerates dopaminergic
neurodegeneration by promoting inflammation, diminishing
neurotrophic factors and promoting oxidation in the SN (Yao
et al., 2015; Af Bjerkén et al., 2019). In this sense, a recent
publication observed that additional lesion of the LC in animal
models of PD promotes enhanced release of interleukins and
cytokines, likely due to an incorrect microglial function, and
aggravates DA neuron degeneration (Yao et al., 2015) although
some authors fails to confirm this cell loss (Iravani et al., 2014).
As commented before, combined dual NA/DA lesions lead to
more severe phenotype including motor and non-motor
symptomatology, probably due to the higher inflammatory
response and faster cell loss (Bharani et al., 2017; Song et al.,
2019). The implication of NA in neuroinflamation and
neuroprotection could have an important translational impact
in the clinic. In this sense, a long-term prospective observatory
study has reported that those patients with chronic respiratory
diseases, that are chronically treated with b2-adrenergic agonists
may have a lower probability of developing PD (Mittal et al.,
2017). One of the reasons for this neuroprotective effect may not
only rely on microglial activation, but also on the ability of b2-
adrenoceptors to down regulate expression of human a-
synuclein genes and moderate protein expression. When
looking for new neuroprotective therapies, it may be relevant
to assure a good NA tone for minimizing the contribution of
neuroinflammation to the neuropathology.
L-DOPA AND THE NORADRENERGIC
SYSTEM
L-DOPA is still considered the most efficient anti-parkinsonian
drug. It is a metabolic precursor of NA through its
decarboxylation into DA by the aromatic amino acid
decarboxylase and the b-hydroxylation of DA by the DA beta-
hydroxylase. Unfortunately, L-DOPA is poorly effective against
non-motor symptoms, does not control some later-onset motor
problems like freezing or “wearing-off” fluctuations, and its long-
term use is associated with dyskinesia and hallucinations
(Olanow et al., 2009; Hirao et al., 2015). The contribution of
the noradrenergic system to LID has been investigated in animal
models using NA/DA neurotoxic lesions. Although some studies
report no implication of the noradrenergic system (Pérez et al.,
2009; Ostock et al., 2014; Ostock et al., 2018), others have
demonstrated that additional noradrenergic lesion worsens
dyskinetic movements in parkinsonian rodents chronically
treated with L-DOPA (Fulceri et al., 2007; Miguelez et al.,
2011b; Shin et al., 2014). Interestingly, in one study, the
authors induced the noradrenergic lesion to already dyskinetic
animals, showing an increase in the duration of the dyskinetic
effect of L-DOPA probably due to impaired striatal DA clearance
(Miguelez et al., 2011b).
Some noradrenergic drugs have proven antidyskinetic
properties in experimental animal models of LID. The a2A-
adrenoceptor antagonist idazoxan, reduced LID, and delayed
their onset without compromising the motor score in MPTP-
treated monkeys. Idazoxan prevented LID appearance while
increasing the locomotor response to L-DOPA (Henry et al.,
1999; Grondin et al., 2000; Fox et al., 2001). Additional a2A-
adrenoceptor antagonists have proven similar antidyskinetic
properties (Gomez-Mancilla and Bédard, 1993; Henry et al.,
1999; Grondin et al., 2000; Savola et al., 2003; Fox and
Brotchie, 2010). Other noradrenergic drugs, as the b-
adrenergic receptor antagonist propranolol and the a2-receptor
agonist clonidine also showed antidyskinetic effects in MPTP-
treated monkeys, at the cost of reducing the antiparkinsonian
efficacy (Gomez-Mancilla and Bédard, 1993). Experiments
performed in 6-OHDA lesioned rats support the prodyskinetic
action of the a2-antagonist atipamezole and the antidyskinetic
effect of propranonol, clonidine, or idazoxan, which did not
worsen motor performance (Dekundy et al., 2007; Gerlach et al.,
2013; Bhide et al., 2015; Ostock et al., 2015). These findings
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suggest that the limited though beneficial effect of clonidine on
LID is probably indirect due to the stimulation of
somatodendritic a2-receptors, which inhibit noradrenergic
neuronal activity and NA release. Some authors also suggest
that the antidyskinetic effect of clonidine may be related to its
sedative properties (Gerlach et al., 2013). Conversely, the
antidyskinetic action of idazoxan, even if it enhances brain NA
release by antagonizing a2 autoreceptors, could be related to the
blockade of a2-receptors expressed by NA receptive cells at
terminal levels. In any case, the overall picture is complex due
to the involvement of the other adrenergic receptor subtypes in
LID. The resulting effect of an overall increase in NA
extracellular on LID is thus uncertain. In contrast to the
beneficial effect of reboxetine (Shin et al., 2014), other NET
inhibitors including desipramine have been reported to
aggravate LID (Arai et al., 2008; Chotibut et al., 2014; Conti
et al., 2016).
As mentioned above, noradrenergic mechanisms are involved
in non-motor symptoms and shape the responses to other
medications such as antidepressant drugs (Eskow Jaunarajs
et al., 2010; Eskow Jaunarajs et al., 2011; Miguelez et al., 2011b;
Miguelez et al., 2013). Noradrenergic neurons may also be
involved in the effects of L-DOPA, but the preclinical data are
not clear. For instance, participation of noradrenergic neurons in
the ability of L-DOPA to enhance DA extracellular levels is likely
an indirect effect that requires the dorsal raphe nucleus (Tanaka
et al., 1999; Navailles et al., 2010; Navailles and De
Deurwaerdère, 2012; De Deurwaerdère et al., 2017; Miguelez
et al., 2017). In dyskinetic rats, lesion of noradrenergic terminals
or neurons did not reduce L-DOPA-stimulated extracellular
levels of DA in the striatum (Navailles et al., 2014; Ostock
et al., 2018). However, the noradrenergic lesion enhanced the
effect of L-DOPA in extrastriatal regions in part due to the loss of
clearance of extracellular DA by noradrenergic fibers bearing
NET (Navailles et al., 2014). Another study found that the
noradrenergic lesion with DSP-4 potentiates L-DOPA-induced
rotations, although this behavioral effect is not directly related to
DA extracellular levels (Pérez et al., 2007). Evidence suggests that
the noradrenergic system participates in the effect of L-DOPA,
but preclinical data are difficult to extrapolate to PD patients
because the noradrenergic fibers, at least from the LC, are
damaged (see above). It is also important to bear in mind that
extracellular striatal DA levels induced by L-DOPA in the
striatum neither parallel motor effects nor abnormal motor
effects (De Deurwaerdère et al., 2017).
Although behavioral data support that noradrenergic drugs
can modulate the effect of L-DOPA, the potential effect of L-
DOPA on NA content or neuron activity is less clear. In the LC,
low doses of L-DOPA did not alter the electrical tonic activity of
noradrenergic neurons in control rats (Miguelez et al., 2013).
Post mortem data vary, reporting no effect, or a decrease in NA
tissue concentration in response to L-DOPA administration
depending on the dose regimen and the brain region studied
(for review see De Deurwaerdère et al., 2017). Acute or chronic
L-DOPA increased NA tissue level in the prefrontal cortex of
normal macaques, but the same regimen decreased NA tissue
level in the prefrontal cortex and the amygdala of MPTP-treated
monkeys whether they were dyskinetic or not (Engeln et al.,
2015). The only difference regarding NA tissue levels between
non-dyskinetic and dyskinetic monkeys was found at the level of
the motor cortex. Studies on L-DOPA-evoked extracellular levels
of NA also show inconclusive results. In this regard, the latest
publications have reported a substantial increase in striatal NA
release after L-DOPA administration (Wang et al., 2014; Ostock
et al., 2018). However, in one study NA levels were still excessive
after noradrenergic neurons were destroyed (Ostock et al., 2018).
It is likely that other electrochemically active compounds were
confounding the chromatograms (Chagraoui et al., 2019). Other
data indicate that L-DOPA either inhibits or does not alter NA
release in the cortex (Dayan and Finberg, 2003; Pascucci
et al., 2012).
CONCLUSION
The identification of noradrenergic mechanisms in PD is crucial
for understanding autonomic functions and non-motor
symptomatology, and drugs that target this system may have a
beneficial impact in the quality of life of the patients. One major
difficulty is to extrapolate the results from animal models to
patients where those alterations are variable and depend on the
stage of the disease. Meanwhile, the involvement of the
noradrenergic system in L-DOPA induced therapeutic effects is
controversial, and noradrenergic strategies to limit the side
effects accompanying anti-parkinsonian drugs are still not
firmly established. In summary, and taking into account that
noradrenergic system pathophysiology is a common feature of
PD with other neurodegenerative diseases, such as Alzheimer’s
disease or atypical neurodegenerative dementias, maintenance of
this system integrity may provide a common viable therapeutic
option as neurodegenerative diseases-modifying strategy.
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